Ashish V. Chintakuntlawar
Papers
3
Total Citations
88
H-Index
3
About
Ashish V. Chintakuntlawar is a leading oncologist and clinical researcher whose work focuses on de-escalating treatment for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. His major contributions center on proving that patients with this highly curable cancer can achieve excellent outcomes with significantly less toxic therapy, thereby preserving quality of life. His landmark MC1273 and MC1675 trials—cumulatively cited over 88 times—demonstrate that reduced adjuvant radiation and chemotherapy after transoral robotic surgery can maintain high cure rates while dramatically lowering long-term side effects, such as swallowing dysfunction and other toxicities. Chintakuntlawar’s research has been pivotal in shifting the standard of care toward more personalized, less morbid approaches for HPV-positive patients. His work on 30-day morbidity and mortality further confirms the safety of these de-escalation strategies. By prioritizing both oncologic efficacy and patient well-being, Chintakuntlawar has emerged as a key voice in head and neck oncology, offering a compelling model for how to treat a curable cancer without sacrificing the patient’s future quality of life.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3